Elexacaftor–tezacaftor–ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation

Andrea Gramegna, Martina Contarini, Francesco Bindo, Stefano Aliberti, Francesco Blasi

Research output: Contribution to journalReview articlepeer-review

Fingerprint Dive into the research topics of 'Elexacaftor–tezacaftor–ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation'. Together they form a unique fingerprint.

Medicine & Life Sciences